At a glance
ClinicalIndex Comparison RecordN/ACompleted· 983 enrolled
Drug / intervention
mt-sDNA screening test +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now
In Brief
An observational study evaluating mt-sDNA screening test and Colonoscopy for Colorectal Cancer. Completed, enrolled 983 participants across 39 sites.
Detailed Summary
The primary objective is to confirm the specificity of a multi-target stool DNA test (mt-sDNA), Cologuard, in an average risk population, ages 45-49.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartNov 2018
Primary CompletionJun 2019
TodayJul 2026
First PostedNov 2, 2018
Enrollment StartNov 6, 2018
Primary CompletionJun 18, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.7 years ago
Interventions
mt-sDNA screening testother
Stool samples will be collected by the subject for the mt-sDNA screening test.
Colonoscopyprocedure
Subjects will undergo a screening colonoscopy.